The administration of low-dose lung irradiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response. The present study will evaluate the efficacy of treatment with low-dose pulmonary radiotherapy added to standard support therapy, in hospitalized patients with respiratory symptoms due to COVID-19 pneumonia, who do not experience improvement with conventional medical therapy and are not subsidiaries of ICU
The WHO has officially confirmed that: "Currently, there is no specific pharmacological
available treatment for COVID-19".
Beyond vital support, there are not currently treatment options for Coronavirus disease
(COVID-19) and related pneumonia, the infection caused by Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2). Pulmonary irradiation is an option for the treatment of COVID-19
pneumonia and could be available quickly and with a duration of about 15 minutes of
treatment.
Thoracic irradiation therapy at very low doses (0.5-1.0 Gy) dates back to the 1920s and was
the only effective mean to treat certain infectious and inflammatory diseases prior to the
development of antimicrobial therapies in the 1940s.
The goal is to replicate low-dose radiation therapy, just as it was used 80 years ago for
viral pneumonia with great success. It will be administered for a new disease, pneumonia
caused by COVID-19, for which there is no cure and many people are dying, mainly from severe
acute respiratory syndrome leading to very severe hypoxemic acute respiratory failure
refractory to treatment.
This therapy is expected to remedy acute respiratory syndrome by reducing inflammation, and
it also has a low risk of side effects and toxicities, given the low doses received, more
than one hundred times lower, compared to the usual radiotherapy used to tumor treatment.
Radiation: Lung Low Dose Radiation
The administration of low-dose lung radiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response.
Inclusion Criteria:
- Patients over 65 years old
- Hospitalized with COVID-19 positive not subsidiary of ICU with severe disease defined
by the presence of ALL the following characteristics:
- Presence of unilateral or bilateral pulmonary infiltrates in chest X-ray or
computed tomography (CT).
- Acute respiratory failure expressed by PaO2 / FIO2 <300.
- Lymphopenia ≤0.8 × 109 / L (800 lymphocytes / ml).
- Patients with ≤8 days from the onset of symptoms.
Exclusion Criteria:
- Patient not consent to participate
Hospital Provincial de Castellon
Castellón De La Plana, Castellon, Spain
Investigator: FRANCISCO GARCIA PINON, MSc
Contact: 964354458
Investigator: Carlos Ferrer Albiach, MD
Francisco Garcia Piñón, MSc
964354458
francisco.garpi@hospitalprovincial.es
Carlos Ferrer Albiach, MD, Principal Investigator
Hospital Provincial de Castellon